HIPEC generally isn’t recommended for patients whose cancer has spread beyond the abdomen, since the whole point of the procedure is treating disease confined to the abdominal cavity. It’s also not usually suitable for patients too physically frail to withstand a long, intensive operation, HIPEC surgery can run many hours and demands real physiological reserve to recover from well.

According to Dr. Sandeep Nayak, surgical oncologist in Bangalore with over 24 years of experience treating solid tumors, “Patients sometimes come in hoping HIPEC is an option regardless of how advanced things are, and I understand that hope completely. But offering a major operation that won’t actually help isn’t kindness, it’s just added risk with no real benefit. Being honest about who isn’t a candidate is just as important as knowing who is.”

If HIPEC candidacy is genuinely on the table for your case, our HIPEC treatment page covers what the actual procedure and eligibility assessment involve.

• Imaging and, often, diagnostic laparoscopy assess how much disease is present and where, before any final decision gets made.
• PCI scoring, covered in more depth on our own site, plays a central role in judging whether complete removal is realistic.
• A tumour board reviews every case, weighing cancer type, spread, and the patient’s overall fitness together, not any single factor in isolation.
• Being ruled out for HIPEC doesn’t mean no options remain, systemic chemotherapy and other approaches still apply depending on the case.

We’ve written more about how that scoring system actually works in What Is Peritoneal Cancer Index for HIPEC?, worth reading if PCI already came up in your consultation.

Yes, H. pylori infection can increase the risk of stomach cancer. Although most infected people never develop cancer, persistent H. pylori infection can cause chronic inflammation and progressive changes in the stomach lining that may eventually contribute to cancer in some individuals. Because H. pylori is a treatable infection, testing and appropriate eradication treatment can be an important part of reducing gastric cancer risk in people who are infected. 

Prof. Dr. Sandeep Nayak, surgical oncologist in Bangalore with over 24 years of experience treating gastrointestinal cancers, puts it this way: “H. pylori doesn’t cause cancer overnight. It’s a slow burn, chronic inflammation building up in the stomach lining over years, sometimes decades, before anything turns malignant. That long runway is actually good news, because it means there’s time to catch and treat the infection before it gets that far.”

The connection isn’t immediate, and it isn’t automatic either. Most people carrying the bacteria never develop cancer. But in those who do, the path tends to follow a similar pattern over time.

• Persistent infection triggers chronic gastritis, ongoing inflammation of the stomach lining
• Long-term inflammation can lead to atrophic gastritis, where the stomach lining thins out
• Thinned, damaged tissue is more prone to abnormal cell changes over the years
• Those changes can eventually progress toward gastric adenocarcinoma, the most common type of stomach cancer

None of this happens on a fixed timeline, and factors like diet, smoking, and genetics all play a role alongside the infection itself. If cancer does develop, treatment often needs a team-based approach. Our stomach and esophageal cancer treatment program covers diagnosis, staging, and surgical management for exactly this kind of case.

This is where the answer gets a little less black and white. Guidelines generally lean toward treating the infection once it’s confirmed, but there’s nuance to it.

• Testing usually happens through a breath test, stool test, or endoscopic biopsy
• Treatment typically involves a combination of antibiotics plus an acid-reducing medication
• Eradicating the infection significantly lowers long-term stomach cancer risk, particularly if caught before atrophic changes set in
• Family history or a prior diagnosis of gastric cancer usually makes treatment more urgent rather than optional

This ties back to something we touched on in our post about clear surgical margins and why a clean result at one point doesn’t guarantee the story’s over. H. pylori works on a similar principle in reverse, catching and treating the root cause early changes what happens years down the line.

Yes, male breast cancer is biologically and clinically different from female breast cancer in several meaningful ways, even though the basic treatment approach, surgery, hormone therapy, chemotherapy where needed, shares a lot of common ground. The differences show up more in hormone receptor patterns, typical age at diagnosis, genetic risk factors, and often the stage at which it’s caught.

According to Dr. Sandeep Nayak, surgical oncologist in Bangalore with over 24 years of experience treating solid tumors, “Male breast cancer gets treated too much like a rare footnote of the female disease, and that’s genuinely a problem. It behaves differently in real ways, hormone receptor status especially, and men are often diagnosed later simply because nobody’s watching for it. That delay alone changes outcomes more than biology does in a lot of cases.”

If a lump or change is what brought you here, our Breast Cancer treatment page covers the diagnostic and treatment pathway that applies regardless of gender.

• Because male breast cancer is so consistently hormone receptor-positive, hormone therapy plays an even more central role in treatment than it sometimes does for women.
• BRCA2 mutations show up disproportionately often in male breast cancer, which makes genetic counselling and family testing a bigger part of the conversation.
• Later-stage diagnosis in men isn’t due to a more aggressive disease, it largely comes down to lower awareness and no routine screening prompting an earlier look.
• Treatment protocols, surgery, radiation, hormone therapy, largely mirror female breast cancer treatment, adapted where male-specific biology calls for it.

We covered the basic awareness side of this question separately in Can Men Get Breast Cancer?, worth reading first if this is a new area for you.

Dr. Sandeep Nayakhas spent more than two decades in surgical oncology, and breast cancer, including the far less commonly discussed male presentation, has been a consistent part of that work throughout. He currently serves as Chairman of Oncology Services for Karnataka and heads Surgical Oncology and Robotic Surgery at KIMS Hospital, Bangalore. What tends to matter most to patients isn’t the title though, it’s that male breast cancer gets taken as seriously and diagnosed as promptly as it would be in a woman, not dismissed or delayed because it’s rare. That seriousness is often where things get missed elsewhere.

Noticed something unusual and unsure if it’s worth getting checked? It is. Call +91 9482202240 and get someone to actually walk you through it.

References

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

If the tumour is still confined to the kidney, surgery is what cures it, and no drug regimen has taken that job over outside clinical trials. Where immunotherapy does matter is around the operation: after it, for people whose pathology looks high risk, and as the main treatment once the cancer has spread.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “The question I hear most is whether a drug can save the operation. For a tumour still inside the kidney, no. Immunotherapy earns its place when the risk of the cancer coming back is high, or when it has already left the kidney.” 

• If the cancer hasn’t left the kidney, taking it out is the treatment with a cure in mind. That hasn’t changed. This is what kidney cancer surgery is built around at this stage.
• Smaller tumours in a good position can often be removed with a partial nephrectomy, so the rest of the kidney keeps working. That matters more than people expect, especially years later.
• Big tumours, or ones that have grown into the renal vein, may need the whole kidney out. Robotic or laparoscopic routes are used when the anatomy allows, our robotic cancer surgery approach covers how that access actually works.
• Very small masses in older or frail patients? Sometimes we watch, or use ablation. But only after the imaging has been looked at properly.

• After surgery, for selected high-risk patients. A year of pembrolizumab has been shown to lower the chance of recurrence, with longer follow-up suggesting a survival benefit too.
• When the cancer has spread, it has become the backbone of treatment, usually as a combination of two immunotherapy drugs or one paired with a targeted tablet. 
• Do these patients still need surgery? Sometimes, but not automatically. Removing the kidney in advanced disease is decided case by case, and many people start with drugs first. This is where a surgical oncologist’s judgement counts.
• Side effects deserve respect. Immunotherapy can inflame the thyroid, gut, liver, skin or lungs, so a new symptom should be reported early rather than at the next visit.

Yes, stomach cancer treatment without full stomach removal may be possible in some cases, but it depends largely on how early the cancer is detected and how deeply it has grown into the stomach wall. Early-stage cancers confined to the lower or upper portion of the stomach can often be treated with a partial gastrectomy, which removes only the affected section rather than the entire stomach.

According to Dr. Sandeep Nayak, surgical oncologist in Bangalore with over 24 years of experience treating solid tumors, “Patients assume a stomach cancer diagnosis automatically means losing the whole stomach, and that fear stops some of them from even getting evaluated properly. Location and depth decide this, not the diagnosis itself. A tumour confined to one part of the stomach, caught early, often doesn’t need total removal at all.”

This decision runs through the same Stomach and Oesophageal Cancer treatment pathway, where imaging and staging determine which approach actually applies to a given case.

• Tumour location matters most, cancers in the lower stomach are far more likely to be candidates for partial removal than ones in the middle or spanning multiple regions.
• Depth of invasion into the stomach wall changes the calculation significantly, deeper invasion generally pushes toward more extensive removal.
• Lymph node involvement, checked during staging, factors heavily into how much surrounding tissue needs to come out along with the tumour.
• Overall health and nutritional status also weigh into what a patient can safely tolerate and recover well from.

This staging and decision process ties closely into how laparoscopic and minimally invasive approaches are increasingly used for early and locally advanced gastric cancer, worth reading if you’re weighing surgical approach as well as extent of removal.